2022
DOI: 10.2147/dddt.s281631
|View full text |Cite
|
Sign up to set email alerts
|

Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy

Abstract: Small interfering ribonucleic acids [siRNAs] are short ribonucleic acid (RNA) fragments cleaved from double-stranded RNA molecules that target and bind to specific sequences on messenger RNA (mRNA), leading to their destruction. Therefore, the siRNA down-regulates the formation of selected mRNAs and their protein products. Givosiran is one such siRNA that uses this mechanism to treat acute hepatic porphyrias. Acute hepatic porphyrias are a group of rare, inherited metabolic disorders, characterized by acute po… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
27
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(27 citation statements)
references
References 83 publications
0
27
0
Order By: Relevance
“…Based upon this case and those reported by Balwani et al [ 14 ], and Ventura et al [ 6 ], it seems likely that givosiran may give rise to potentially severe immune-mediated acute DILI. Thus, although givosiran represents a welcome advance for the treatment of patients with AIP who are experiencing frequent acute attacks, patients initiating therapy should be monitored closely for DILI or other adverse drug reactions during the first 3–4 months and, if tolerated well, periodically thereafter [ [17] , [18] , [19] ].…”
Section: Discussionmentioning
confidence: 99%
“…Based upon this case and those reported by Balwani et al [ 14 ], and Ventura et al [ 6 ], it seems likely that givosiran may give rise to potentially severe immune-mediated acute DILI. Thus, although givosiran represents a welcome advance for the treatment of patients with AIP who are experiencing frequent acute attacks, patients initiating therapy should be monitored closely for DILI or other adverse drug reactions during the first 3–4 months and, if tolerated well, periodically thereafter [ [17] , [18] , [19] ].…”
Section: Discussionmentioning
confidence: 99%
“…The former act through their interplay with the RNA-induced silencing complex (RISC), leading to RNA interference (RNAi), meaning that a siRNA has the potential to target a prespecified mRNA molecule and induce its degradation, completely blocking the expression of a certain gene [ 5 ]. Drugs based on siRNAs have already been launched to treat TTR-amyloidosis and hepatic porphyria [ 6 , 7 ]. Regarding microRNAs, these molecules inhibit target mRNAs by forming a complex with RISC and downstream suppressing mRNA translation or contributing to its degradation or cleavage.…”
Section: Introductionmentioning
confidence: 99%
“…24 , 26 Other management strategies include trigger avoidance, acute attack treatment with intravenous hemin, and hemin prophylaxis. 26 , 27 Hemin use carries acute (e.g., headache, phlebitis) and chronic risks (e.g., iron overload, venous thrombosis/obliteration, central venous catheter complications). 10 , 27 , 28 , 29 For women with attacks associated with the menstrual cycle's luteal phase, gonadotropin‐releasing hormone (GnRH) analogs have been used prophylactically.…”
Section: Introductionmentioning
confidence: 99%
“…Givosiran (Givlaari; Alnylam Pharmaceuticals, Cambridge, MA), a once‐monthly subcutaneous injection, is an ALAS1‐directed small interfering RNA approved for AHP treatment in adults in the United States and adults and adolescents age ≥ 12 years in the European Union 24,25 . Givosiran treatment can lead to nausea, fatigue, injection‐site reactions, serum aminotransferase elevations, decreased estimated glomerular filtration rate, increased blood homocysteine, or anaphylactic reactions in some patients 24,26 . Other management strategies include trigger avoidance, acute attack treatment with intravenous hemin, and hemin prophylaxis 26,27 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation